BACKGROUND: The ability to predict recovery of left ventricular ejection fraction (LVEF) in response to guideline-directed therapy among patients with nonischemic cardiomyopathy is desired. We sought ...

Bayer will present three new prespecified subgroup analyses from the pivotal Phase III FINEARTS-HF cardiovascular outcomes trial investigating KERENDI ...

"Cardiomyopathy" is an umbrella term for diseases of the heart muscle that negatively impact its structure and ...

A manufacturer-funded study found a significant decrease in annual total medical costs in patients with overweight/obesity ...